non glp 1 drugs for weight loss GLP-1 Agonists Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH GLP-1 Weight Loss NYC |

Evaluation and management of residual cardiovascular risk in patients with diabetes

Alanteet AA, Attia HA, Shaheen S, Alfayez M, Alshanawani B

Eur J Pharmacol (2004) 504:13942

Since 2020, the number of prescriptions made for these drugs has tripled, and its estimated that 12% of Americans have used these medications

It can not only influence the fasting blood glucose of patients but also decrease the postprandial blood glucose of patients and have an impact on the glycosylated hemoglobin (HbA1c) of patients (68)

Additionally, a sensitivity analysis was conducted using different correlation coefficients to evaluate the stability of the imputed values for such outcome (sensitivity analysis of ( r ) is provided in Table S6)